TransCode Therapeutics, Inc. RNAZ
1.57 USD -0.06 (-3.68%)
At closeNov 3, 2026, 4:00 PM EST
1.57 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
1.50 Day range 1.61
1.50 52-week range 12.60
- YTD
- -77.01%
- 1 year
- -85.06%
Financial health
Altman Z-Score
-1.94 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
0 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B3 / 5 overall
- DCF 5
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 5
Valuation
P/E -0.1×
FY 2018 5y median -1.4× FY 2025
P/S 0.0×
FY 2018 5y median 0.0× FY 2025
P/B 0.5×
FY 2018 5y median 14.1× FY 2025
P/FCF -0.2×
FY 2018 5y median -1.8× FY 2025
EV/EBITDA 0.4×
FY 2018 5y median -1.2× FY 2025
EV/Sales 0.0×
FY 2018 5y median 0.0× FY 2025
FCF Yield -414.4%
FY 2018 5y median -56.8% FY 2025
Profitability
Gross Margin 0.0%
FY 2018 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2018 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2018 5y median 0.0% FY 2025
ROE -335.4%
FY 2018 5y median -335.4% FY 2025
ROIC -17.6%
FY 2018 5y median -343.4% FY 2025
ROA -21.3%
FY 2018 5y median -229.7% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2018 FY 2025
Operating Income -78.7%
FY 2018 FY 2025
EPS (diluted) -11.6%
FY 2018 FY 2025
Free Cash Flow -46.2%
FY 2018 FY 2025
Financial Health
Current Ratio 6.3×
FY 2018 5y median 2.6× FY 2025
Quick Ratio 6.3×
FY 2018 5y median 2.6× FY 2025
Debt / Equity 0.0×
FY 2018 5y median 0.0× FY 2025
Net Debt / EBITDA 0.5×
FY 2018 5y median 0.4× FY 2025
Interest Coverage -4229×
FY 2018 5y median -347× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31